Investing.com - Nabriva (NASDAQ:NBRV) Therapeutics reported on Thursday first quarter earnings that missed analysts' forecasts and revenue that fell short of expectations.
Nabriva Therapeutics announced earnings per share of $-0.2 on revenue of $8.02M. Analysts polled by Investing.com anticipated EPS of $-0.185 on revenue of $11.03M.
Nabriva Therapeutics shares are down 51.61% from the beginning of the year, still down 87.34% from its 52 week high of $2.29 set on May 26, 2021. They are under-performing the Nasdaq which is down 21.27% from the start of the year.
Nabriva Therapeutics shares gained 1.62% in after-hours trade following the report.
Nabriva Therapeutics follows other major Healthcare sector earnings this month
Nabriva Therapeutics's report follows an earnings beat by J&J on April 19, who reported EPS of $2.67 on revenue of $23.43B, compared to forecasts EPS of $2.59 on revenue of $23.62B.
UnitedHealth had beat expectations on April 14 with first quarter EPS of $5.49 on revenue of $80.15B, compared to forecast for EPS of $5.36 on revenue of $78.73B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar